Nanobiotix (NBTX) Receivables - Other (2019 - 2025)

Nanobiotix's Receivables - Other history runs 7 years deep, the most recent figure standing at $2.5 million for Q4 2025.

• On a quarterly basis, Receivables - Other fell 21.76% year-over-year to $2.5 million in Q4 2025; TTM through Dec 2025 was $2.5 million, a 21.76% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 24.06% from the prior year.
• Receivables - Other climbed to $2.5 million in Q4 2025 per NBTX's latest filing, from -$701815.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $3.9 million in Q4 2021 and bottomed at -$9.0 million in Q2 2021.
• The 5-year median for Receivables - Other is $847377.1 (2023), against an average of $324953.5.
• Across the five-year window, Receivables - Other jumped 252.29% in 2021 and plunged 515.1% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $3.9 million in 2021, then dropped by 27.63% to $2.8 million in 2022, then tumbled by 45.44% to $1.5 million in 2023, then surged by 108.3% to $3.2 million in 2024, then dropped by 21.76% to $2.5 million in 2025.
• Per Business Quant, the three latest NBTX Receivables - Other figures stand at $2.5 million (Q4 2025), -$701815.0 (Q2 2025), and $3.2 million (Q4 2024).